On. Target Molecules Biotech Inc has created a novel technology platform to accelerate advancements in cancer research. The company is commencing detailed pre-clinical studies, including IND-enabling studies, to develop, obtain regulatory approval for, and commercialize many variations of its sequenced and patented monoclonal antibodies against all indications of cancer.
We are in the process of developing our anti-cancer molecule for several cancers which include - Melanoma, Breast, Bladder, Cervical, Liver, Prostate, and Glioblastoma cancer. The Architecture of the Fusion Protein is the key that locks onto a Bio-marker expressed in Cancer Cells. The antibody causes apoptosis at 75% in 7 days.
The Company will continue to develop and introduce various molecules from its patented biotech platform.
On. Target Molecules Biotech Inc will bio-engineer more anti cancer molecules in the product pipeline in a relatively short span of time
An overview of the efficacy of O.TM Biotech’s antibody which causes an average Apoptosis (natural cell death) at 75 % in 7 days with two doses in-vitro. O.TM Biotech has produced molecules of high caliber tested on 24 cancer cell lines with great results.
Cancer Cells imaged at O.TM Biotech Lab
O.TM Biotech is developing anti-cancer molecules for several cancers
PRODUCT DEVELOPMENT IN THE PIPELINE
Biodegradable and bio-compatible polymer mimics of molecules that target cancer bio-markers.
Develop molecularity imprinted polymers designed to have molecular recognition to the biologic template.
The polymer formulating machine and the imprint process leading to sensors and therapeutic mimics are in the process of IP filing
Nanoparticles which target cancer cells act as antennae for RF from a RF device and ablate cells. The RF ablation IP surrounds the RF machine and the nanoparticles which act as heat flux agents
O.TM BIOTECH INC UNCW Crest Research Park 5598 Marvin K. Moss Lane Wilmington NC 28409 USA